For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $639.15 in the prior trading day, Idexx Laboratories, Inc (NASDAQ: IDXX) closed at $637.34, down -0.28%. In other words, the price has decreased by -$0.28 from its previous closing price. On the day, 0.52 million shares were traded. IDXX stock price reached its highest trading level at $651.5 during the session, while it also had its lowest trading level at $628.17.
Ratios:
Our goal is to gain a better understanding of IDXX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 309.80 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 65.01. For the most recent quarter (mrq), Quick Ratio is recorded 0.74 and its Current Ratio is at 1.06. In the meantime, Its Debt-to-Equity ratio is 0.85 whereas as Long-Term Debt/Eq ratio is at 0.38.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, UBS on October 01, 2025, initiated with a Neutral rating and assigned the stock a target price of $720.
On August 05, 2025, BTIG Research reiterated its Buy rating and also lowered its target price recommendation from $545 to $785.
On July 01, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $625.Jefferies initiated its Buy rating on July 01, 2025, with a $625 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 22 ’25 when SZOSTAK M ANNE sold 2,187 shares for $647.33 per share. The transaction valued at 1,415,700 led to the insider holds 262 shares of the business.
MARGARET ANNE SZOSTAK bought 2,187 shares of IDXX for $1,415,700 on Aug 22 ’25. On Aug 12 ’25, another insider, Erickson Michael G, who serves as the Executive Vice President of the company, sold 406 shares for $649.96 each. As a result, the insider received 263,813 and left with 11,287 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IDXX now has a Market Capitalization of 50990194688 and an Enterprise Value of 52062867456. As of this moment, Idexx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 53.05, and their Forward P/E ratio for the next fiscal year is 45.01. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.64. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.63 while its Price-to-Book (P/B) ratio in mrq is 35.02. Its current Enterprise Value per Revenue stands at 12.894 whereas that against EBITDA is 37.379.
Stock Price History:
The Beta on a monthly basis for IDXX is 1.62, which has changed by 0.39236248 over the last 52 weeks, in comparison to a change of 0.13033986 over the same period for the S&P500. Over the past 52 weeks, IDXX has reached a high of $688.12, while it has fallen to a 52-week low of $356.14. The 50-Day Moving Average of the stock is -0.49%, while the 200-Day Moving Average is calculated to be 23.83%.
Shares Statistics:
The stock has traded on average 544.41K shares per day over the past 3-months and 387690 shares per day over the last 10 days, according to various share statistics. A total of 80.15M shares are outstanding, with a floating share count of 79.14M. Insiders hold about 1.08% of the company’s shares, while institutions hold 94.38% stake in the company. Shares short for IDXX as of 1759190400 were 1857579 with a Short Ratio of 3.41, compared to 1756425600 on 2049291. Therefore, it implies a Short% of Shares Outstanding of 1857579 and a Short% of Float of 3.04.
Earnings Estimates
The dynamic stock of Idexx Laboratories, Inc (IDXX) is currently being evaluated by a team of 10.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $2.9, with high estimates of $3.02 and low estimates of $2.72.
Analysts are recommending an EPS of between $12.78 and $12.4 for the fiscal current year, implying an average EPS of $12.63. EPS for the following year is $14.19, with 11.0 analysts recommending between $14.37 and $14.0.
Revenue Estimates
10 analysts predict $1.07B in revenue for. The current quarter. It ranges from a high estimate of $1.08B to a low estimate of $1.06B. As of. The current estimate, Idexx Laboratories, Inc’s year-ago sales were $975.54MFor the next quarter, 10 analysts are estimating revenue of $1.06B. There is a high estimate of $1.07B for the next quarter, whereas the lowest estimate is $1.04B.
A total of 13 analysts have provided revenue estimates for IDXX’s current fiscal year. The highest revenue estimate was $4.26B, while the lowest revenue estimate was $4.2B, resulting in an average revenue estimate of $4.23B. In the same quarter a year ago, actual revenue was $3.9BBased on 13 analysts’ estimates, the company’s revenue will be $4.58B in the next fiscal year. The high estimate is $4.64B and the low estimate is $4.5B.
